Symposium examines latest treatments of atrial fibrillation

January 2010
Medical Device Daily;1/26/2010, Vol. 14 Issue 16, p1
The article discusses the highlights of the 15th annual Boston Atrial Fibrillation Symposium that was held in Boston, Massachusetts. The event was attended by EP industry clinicians, aspiring entrepreneurs and the investment community. A comprehensive review of atrial fibrillation clinical trials was presented by Hugh Calkins of Johns Hopkins Heart and Vascular Institute.


Related Articles

  • Impressions from the 2012 Boston AF Symposium. Waldo, Albert L. // Cardiology Today;Mar2012, Vol. 15 Issue 3, p4 

    The author offers his views on the 2012 Boston Atrial Fibrillation Symposium.

  • Atrial Fibrillation.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article informs that the Atrial Fibrillation 2012 conference will be held on June 26, 2012 in London, England.

  • ECAS 2009 SCIENTIFIC PROGRAM.  // Journal of Interventional Cardiac Electrophysiology;Apr2009, Vol. 24 Issue 3, p163 

    The article presents information on several workshops including a workshop on ablation of atrial fibrillation in next five years to be held on April 19, 2009 in California, a workshop on abstracts session to be held on April 20, 2009 in Paris, France, and a concurrent workshop on ablation of...

  • Guidelines to outcomes: clinical leadership in atrial fibrillation.  // British Journal of Hospital Medicine (17508460);May2009, Vol. 70 Issue 5, p288 

    In December 2008, delegates attending a symposium in Barcelona sponsored by sanofi-aventis on atrial fibrillation debated how clinical care could be improved to meet the challenge of caring for increasing numbers of patients with atrial fibrillation and preventing its complications. This report...

  • The Role of and Selection Process for the New Anticoagulants in Nonvalvular Atrial Fibrillation. Reiffel, James; Halperin, Jonathan; Kowey, Peter; Naccarelli, Gerald // Medical Roundtable: Cardiovascular Edition;Fall2012, Vol. 3 Issue 3, p143 

    Information on the Expert Roundtable Discussion held in the U.S. on August 3, 2012 is presented. Topics include pharmacology of new anticoagulants, advantages and disadvantages of warfarin, and nonvalvular atrial fibrillation's definition. Discussants are Jonathan Halperin, Peter Kowey, and...

  • Atrial fibrillation device market sets pace for CA conference presenters. HAIMOVITCH, LARRY // Medical Device Daily;11/13/2009, Vol. 13 Issue 220, p1 

    The article discusses the highlights of the annual Camaccord Adams Cardiovascular Conference held in San Francisco, California. One of the most talked about topic during the conference was atrial fibrillation (AF) which has become a big health care problem in the country. Companies that...

  • Should Anticoagulation Be Stopped After Successful Ablation for Atrial Fibrillation? Callans, David; Connolly, Stuart; Natale, Andrea // Medical Roundtable: Cardiovascular Edition;Fall2011, Vol. 2 Issue 4, p235 

    The discussion focused primarily on: (1) the likelihood of atrial fibrillation (AF) in patients after successful ablation; (2) discontinuation of medication and implementation of monitoring; (3) the intensity of monitoring and whether it really works; and (4) the ultimate decision made by both...

  • 11th Annual Congress of the European Cardiac Arrhythmia Society Paris April 19-21, 2015 Scientific Program and Abstract Special issue.  // Journal of Interventional Cardiac Electrophysiology;Apr2015, Vol. 42 Issue 3, p173 

    The article offers information on the 11th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) to be held in Paris, France from April 19-21, 2015 that will present different session on atrial fibrillation ablation, prevention of sudden cardiac death and ventricular arrhythmias.

  • Development of post-dronedarone agents slow, but progress being made. Eliis, Brian // Cardiology Today;Feb2011, Vol. 14 Issue 2, p14 

    The article focuses on the presentation of Peter Kowey of Jefferson Medical College at the 2011 Atrial Fibrillation Symposium in Boston, Massachusetts wherein he discussed the potential of celivarone, budiodarone and vernakalant as antiarrhythmic agents.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics